CLOs on the Move

Sinochem Jiangsu Co.

www.sinochemjiangsu.com

 
Sinochem Jiangsu Co. is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

MedSpeed

Healthcare is changing. Healthcare organizations are growing. Care continues to expand outside of the hospital walls. This provides more capacity to utilize scale to create healthcare companies that are better functioning, smarter organizations. Intra-company logistics - the enterprise-wide movement of physical materials, such as blood and specimens, pharmaceuticals and supplies - is the foundation of the healthcare supply chain. Healthcare organizations, especially those providing service to patients` homes, need transportation to function. With 130+ locations in 29 states, MedSpeed is the market-leading organization that is changing the way the healthcare industry views transportation by leveraging it to help organizations integrate and operate more effectively.

Protech Dental Studio

Protech Dental Studio is a Sterling, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Family Service of Rhode Island

We are one of the oldest and largest non-profit human service agencies in Rhode Island. Our offices are located in Providence and North Kingstown, with children's residential treatment facilities in Smithfield, North Smithfield, Bristol, and East

UAB Huntsville Regional Medical Campus

UAB Huntsville Regional Medical Campus is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Enterin Inc.

Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.